Searching for a system: The quest for ovarian cancer biomarkers

Cancer Biomarkers

Volumn 8, Issue 4-5, 2010, Pages 223-230

  Rodland, Karin D ^a   Maihle, Nita J ^b  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; diagnostics; early detection; Ovarian cancer; systems biology

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72 4 ANTIGEN; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; INHIBIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; MESOTHELIN; MUCIN 1; NEUROPSIN; OSTEOPONTIN; PROLACTIN; RNA; SERUM AMYLOID A; SOMATOMEDIN B; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ALGORITHM; ARTICLE; ASSAY; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CERTIFICATION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEALTH CARE COST; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LABORATORY TEST; MASS SPECTROMETRY; MEDICAL TECHNOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SERUM; STATISTICAL ANALYSIS; SUPPORT VECTOR MACHINE; TRANSCRIPTOMICS; TRANSVAGINAL ECHOGRAPHY;

ANIMALS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 81155123595     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0216     Document Type: Article

References (60)

1. L. Ries, D. Melbert, M. Krapcho, A. Mariotto and B. Miller, Seer cancer statistics review, 1975-2004, Posted to SEERWebsite (2007).
2. N. Calogne, Screening for ovarian cancer: Recommendation statement, Ann Fam Med 2 (2004), 260-262.
3. J.S. Mandelblatt, K.A. Cronin, S. Bailey, D.A. Berry, H.J. de Koning, G. Draisma, H. Huang, S.J. Lee, M. Munsell, S.K. Plevritis, P. Ravdin, C.B. Schechter, B. Sigal,M.A. Stoto, N.K. Stout, N.T. van Ravesteyn, J. Venier, M. Zelen and E.J. Feuer, Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms, Ann Intern Med 151 (2009), 738-747.
4. K. Wang, S. Zhang, J. Weber, D. Baxter and D.J. Galas, Export of microRNAs and microRNA-protective protein by mammalian cells, Nucleic Acids Res 38, 7248-7259.
5. A.M. Lutz, J.K. Willmann, F.V. Cochran, P. Ray and S.S. Gambhir, Cancer screening: A mathematical model relatingsecreted blood biomarker levels to tumor sizes, PLoS Med 5 (2008), e170.
6. D.F. Ransohoff, How to improve reliability and efficiency of research about molecular markers: Roles of phases, guidelines, and study design, J Clin Epidemiol 60 (2007), 1205-1219. (Pubitemid 350061148)
7. D.F. Ransohoff, Lessons from controversy: Ovarian cancer screening and serum proteomics, J Natl Cancer Inst 97 (2005), 315-319. (Pubitemid 40310281)
8. E.P.Diamandis, Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems, J Natl Cancer Inst 96 (2004), 353-356.
9. M.S. Pepe, Z. Feng, H. Janes, P.M. Bossuyt and J.D. Potter, Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design, J Natl Cancer Inst 100 (2008), 1432-1438.
10. R.C. Bast, Jr., M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin and R.C. Knapp, Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Invest 68 (1981), 1331-1337. (Pubitemid 12235035)
11. R.C. Bast, Jr., T.L.Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus, R.S. Berkowitz, T. Leavitt, C.T. Griffiths, L. Parker, V.R. Zurawski, Jr. and R.C. Knapp, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 309 (1983), 883-887. (Pubitemid 13014028)
12. B.W. Yin and K.O. Lloyd, Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, muc16, J Biol Chem 276 (2001), 27371-27375.
13. Y. Wang, D.J. Cheon, Z. Lu, S.L. Cunningham, C.M. Chen, R.Z. Luo, D. Xing, S. Orsulic, R.C. Bast, Jr. and R.R. Behringer, Muc16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse, Differentiation 76 (2008), 1081-1092.
14. R.C. Bast, Jr., D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K.A. Baggerly, E.N. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs and K. Lu, New tumor markers: CA125 and beyond, Int J Gynecol Cancer 15(Suppl 3) (2005), 274-281. (Pubitemid 43096594)
15. R.C. Bast, Jr., Ca 125 and the detection of recurrent ovarian cancer: A reasonably accurate biomarker for a difficult disease, Cancer 116 (2010), 2850-2853.
16. R.C. Bast, Jr., N. Urban, V. Shridhar, D. Smith, Z. Zhang, S. Skates, K. Lu, J. Liu, D. Fishman and G.Mills, Early detection of ovarian cancer: Promise and reality, Cancer Treat Res 107 (2002), 61-97.
17. Z. Zhang, Y. Yu, F. Xu, A. Berchuck, C. van Haaften-Day, L.J. Havrilesky, H.W. de Bruijn, A.G. van der Zee, R.P.Woolas, I.J. Jacobs, S. Skates, D.W. Chan and R.C. Bast, Jr., Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer, Gynecol Oncol 107 (2007), 526-531. (Pubitemid 350160868)
18. S.S. Buys, E. Partridge, M.H. Greene, P.C. Prorok, D. Reding, T.L. Riley, P. Hartge, R.M. Fagerstrom, L.R. Ragard, D. Chia, G. Izmirlian, M. Fouad, C.C. Johnson and J.K. Gohagan, Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial, Am J Obstet Gynecol 193 (2005), 1630-1639. (Pubitemid 41540458)
19. U. Menon, A. Gentry-Maharaj, R. Hallett, A. Ryan, M. Burnell, A. Sharma, S. Lewis, S. Davies, S. Philpott, A. Lopes, K. Godfrey, D. Oram, J. Herod, K. Williamson, M.W. Seif, I. Scott, T. Mould, R. Woolas, J. Murdoch, S. Dobbs, N.N. Amso, S. Leeson, D. Cruickshank, A. McGuire, S. Campbell, L. Fallowfield, N. Singh, A. Dawnay, S.J. Skates, M. Parmar and I. Jacobs, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (ukctocs), Lancet Oncol 10 (2009), 327-340.
20. M.R. Andersen, B.A.Goff, K.A. Lowe,N. Scholler, L. Bergan, C.W. Dresher, P. Paley and N. Urban, Combining a symptoms index with CA125 to improve detection of ovarian cancer, Cancer 113 (2008), 484-489.
21. S.C. Mok, K.K.Wong, R.K. Chan, C.C. Lau, S.W. Tsao, R.C. Knapp and R.S. Berkowitz, Molecular cloning of differentially expressed genes in human epithelial ovarian cancer, Gynecol Oncol 52 (1994), 247-252. (Pubitemid 24064379)
22. C. Palmer, X. Duan, S. Hawley, N. Scholler, J.D. Thorpe, R.A. Sahota, M.Q. Wong, A. Wray, L.A. Bergan, C.W. Drescher, M.W. McIntosh, P.O. Brown, B.H. Nelson and N. Urban, Systematic evaluation of candidate blood markers for detecting ovarian cancer, PLoS One 3 (2008), e2633.
23. K. Hibbs, K.M. Skubitz, S.E. Pambuccian, R.C. Casey, K.M. Burleson, T.R. Oegema, Jr., J.J. Thiele, S.M. Grindle, R.L. Bliss and A.P. Skubitz, Differential gene expression in ovarian carcinoma: Identification of potential biomarkers, AmJ Pathol 165 (2004), 397-414. (Pubitemid 38971371)
24. A.B. Tchagang, A.H. Tewfik, M.S. DeRycke, K.M. SkubitzandA.P. Skubitz, Early detection of ovarian cancer using group biomarkers, Mol Cancer Ther 7 (2008), 27-37.
25. K.H. Lu, A.P. Patterson, L. Wang, R.T. Marquez, E.N. Atkinson, K.A. Baggerly, L.R. Ramoth, D.G. Rosen, J. Liu, I. Hellstrom, D. Smith, L. Hartmann, D. Fishman, A. Berchuck, R. Schmandt, R. Whitaker, D.M. Gershenson, G.B. Mills and R.C. Bast, Jr., Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis, Clin Cancer Res 10 (2004), 3291-3300. (Pubitemid 38685433)
26. C.D. Hough, K.R. Cho, A.B. Zonderman, D.R. Schwartz and P.J. Morin, Coordinately up-regulated genes in ovarian cancer, Cancer Res 61 (2001), 3869-3876. (Pubitemid 32720943)
27. M. Shih Ie and B. Davidson, Pathogenesis of ovarian cancer: Clues from selected overexpressed genes, Future Oncol 5 (2009), 1641-1657.
28. M.A. Merritt, P.G. Parsons, T.R. Newton, A.C. Martyn, P.M. Webb, A.C. Green, D.J. Papadimos and G.M. Boyle, Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer, BMC Cancer 9 (2009), 378.
29. G. Mor, I.Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward and D.C. Ward, Serum protein markers for early detection of ovarian cancer, Proc Natl Acad Sci U S A 102 (2005), 7677-7682. (Pubitemid 40741030)
30. E. Gorelik, D.P. Landsittel, A.M. Marrangoni, F. Modugno, L. Velikokhatnaya, M.T. Winans, W.L. Bigbee, R.B. Herberman and A.E. Lokshin, Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer, Cancer Epidemiol Biomarkers Prev 14 (2005), 981-987. (Pubitemid 40478567)
31. Z. Zhang, R.C. Bast, Jr., Y. Yu, J. Li, L.J. Sokoll, A.J. Rai, J.M. Rosenzweig, B. Cameron, Y.Y. Wang, X.Y. Meng, A. Berchuck, C. Van Haaften-Day, N.F. Hacker, H.W. de Bruijn, A.G. van der Zee, I.J. Jacobs, E.T. Fung and D.W. Chan, Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, Cancer Res 64 (2004), 5882-5890. (Pubitemid 39095590)
32. Z. Zhang and D.W. Chan, The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers, Cancer Epidemiol Biomarkers Prev 19 (2010), 2995-2999.
33. G.P. Bertenshaw, P. Yip, P. Seshaiah, J. Zhao, T.H. Chen,W.S. Wiggins, J.P. Mapes and B.C. Mansfield, Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 17 (2008), 2872-2881.
34. S.D. Amonkar, G.P. Bertenshaw, T.H. Chen, K.J. Bergstrom, J. Zhao, P. Seshaiah, P. Yip and B.C. Mansfield, Development and preliminary evaluation of a multivariate index assay for ovarian cancer, PLoS One 4 (2009), e4599.
35. Z.Yurkovetsky, S. Skates, A. Lomakin, B.Nolen, T. Pulsipher, F. Modugno, J. Marks, A. Godwin, E. Gorelik, I. Jacobs, U. Menon, K. Lu, D. Badgwell, R.C. Bast, Jr. and A.E. Lokshin, Development of a multimarker assay for early detection of ovarian cancer, J Clin Oncol 28 (2010), 2159-2166.
36. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C.Miller, W.J. Allard,W. Gajewski, R. Kurman, R.C. Bast, Jr. and S.J. Skates, A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass, Gynecol Oncol 112 (2009), 40-46.
37. B. Nolen, A. Marrangoni, L. Velikokhatnaya, D. Prosser, M. Winans, E. Gorelik and A. Lokshin, A serum based analysis of ovarian epithelial tumorigenesis, Gynecol Oncol 112 (2009), 47-54.
38. A.T. Baron, C.H. Boardman, J.M. Lafky, A. Rademaker, D. Liu, D.A. Fishman, K.C. Podratz and N.J. Maihle, Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 14 (2005), 306-318. (Pubitemid 40270090)
39. M. Kobel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, C. Palmer, S. Leung, N.J. Bowen, D.N. Ionescu, A. Rajput, L.M. Prentice, D. Miller, J. Santos, K. Swenerton, C.B. Gilks and D. Huntsman, Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies, PLoS Med 5 (2008), e232.
40. C.M. Perou and A.L. Borresen-Dale, Systems biology and genomics of breast cancer, Cold Spring Harb Perspect Biol.
41. S. Koscielny, Critical review of microarray-based prognostic tests and trials in breast cancer, Curr Opin Obstet Gynecol 20 (2008), 47-50.
42. L. Dubeau, The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol Oncol 72 (1999), 437-442. (Pubitemid 29118208)
43. K. Levanon, C. Crum and R. Drapkin, New insights into the pathogenesis of serous ovarian cancer and its clinical impact, J Clin Oncol 26 (2008), 5284-5293.
44. J.M. Piek, P. Kenemans and R.H. Verheijen, Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause, Am J Obstet Gynecol 191 (2004), 718-732. (Pubitemid 39298100)
45. L. Bingle, S.S. Cross, A.S. High, W.A. Wallace, D. Rassl, G. Yuan, I. Hellstrom, M.A. Campos and C.D. Bingle, WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung, Respir Res 7 (2006), 61.
46. R. Drapkin, H.H. von Horsten, Y. Lin, S.C. Mok, C.P. Crum, W.R. Welch and J.L. Hecht, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res 65 (2005), 2162-2169. (Pubitemid 40490123)
47. K. Chang and I. Pastan, Molecular cloning ofmesothelin, a differentiation ntigen present on mesothelium, mesotheliomas, and ovarian cancers, Proc Natl Acad Sci U S A 93 (1996), 136-140. (Pubitemid 26041483)
48. O. Kaneko, L. Gong, J. Zhang, J.K. Hansen, R. Hassan, B. Lee and M. Ho, A binding domain on mesothelin for CA125/MUC16, J Biol Chem 284 (2009), 3739-3749.
49. N. Uehara, Y.Matsuoka and A. Tsubura,Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells, Mol Cancer Res 6 (2008), 186-193. (Pubitemid 351342406)
50. G. Dennis, Jr., B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, H.C. Lane and R.A. Lempicki, David: Database for annotation, visualization, and integrated discovery, Genome Biol 4 (2003), P3.
51. R.G.Moore, A.K. Brown, M.C.Miller, S. Skates,W.J. Allard, T. Verch, M. Steinhoff, G. Messerlian, P. DiSilvestro, C.O. Granai and R.C. Bast, Jr., The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol 108 (2008), 402-408. (Pubitemid 351174295)
52. I. Simon,Y. Liu, K.L. Krall, N. Urban, R.L.Wolfert, N.W. Kim and M.W. McIntosh, Evaluation of the novel serum markers B7-H4, spondin 2, and DCR3 for diagnosis and early detection of ovarian cancer, Gynecol Oncol 106 (2007), 112-118. (Pubitemid 46898578)
53. Z. Yurkovetsky, S. Ta'asan, S. Skates, A. Rand, A. Lomakin, F. Linkov, A. Marrangoni, L. Velikokhatnaya, M. Winans, E. Gorelik, G.L. Maxwell, K. Lu and A. Lokshin, Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin, Gynecol Oncol 107 (2007), 58-65. (Pubitemid 47464542)
54. A.T. Baron, J.M. Lafky and C.H. Boardman, S. Balasubramaniam, V.J. Suman, K.C. Podratz and N.J. Maihle, Serum sERBB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer, Cancer Epidemiol Biomarkers Prev 8 (1999), 129-137. (Pubitemid 29085379)
55. A.T. Baron, J.M. Lafky, C.H. Boardman, E.M.Cora, M.C. Buenafe, D. Liu, A. Rademaker, D.A. Fishman, K.C. Podratz, J.L. Reiter and N.J. Maihle, Soluble epidermal growth factor receptor: A biomarker of epithelial ovarian cancer, Cancer Treat Res 149 (2009), 189-202.
56. M.W. McIntosh, Urban, N.; Karlan, B., Generating longitudinal screening algorithms using novel biomarkers for disease, Cancer Epidemiol Biomarkers Prev 11 (2002), 159-166. (Pubitemid 34202997)
57. D.J. Slamon,W. Godolphin, L.A. Jones, J.A. Holt, S.G.Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich et al., Studies of the HER-2/NEU proto-oncogene in human breast and ovarian cancer, Science 244 (1989), 707-712. (Pubitemid 19147683)
58. E. Hogdall, E.T. Fung, I.J. Christensen, C. Yip, L. Nedergaard, S.A. Engelholm, S. Risum, A.L. Petri, L. Lundvall, L. Lomas and C. Hogdall, Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients, Proteomics Clin Appl 4, 940-952.
59. M.S. Derycke, S.E. Pambuccian, C.B. Gilks, S.E. Kalloger, A. Ghidouche, M. Lopez, R.L. Bliss, M.A. Geller, P.A. Argenta, K.M. Harrington and A.P. Skubitz, Nectin 4 overexpression in ovarian cancer tissues and serum: Potential role as a serum biomarker, Am J Clin Pathol 134, 835-845.
60. J.D. Andersen, K.L. Boylan, F.S. Xue, L.B. Anderson, B.A. Witthuhn, T.W. Markowski, L. Higgins andA.P. Skubitz, Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis, Electrophoresis 31, 599-610.